Hu Y X, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Okai T, Sawabu N
Department of Internal Medicine, Cancer Research Institute, Kanazawa University, 4-86 Yoneizumi, Kanazawa 921, Japan.
Clin Cancer Res. 1997 Sep;3(9):1473-7.
Expression of the p16 gene product in human primary pancreatic carcinoma (PC) was investigated in paraffin-embedded tissue using a monoclonal antibody against p16 protein, clone G175-405, by means of immunohistochemistry, and the correlation of results with various clinicopathological parameters was evaluated. All six cases of normal pancreas and all but 1 of 20 cases of chronic pancreatitis expressed p16 protein, whereas 37.5% (3 of 8) of cystadenomas and 41. 9% (26 of 62) of PCs lost p16 expression. There was a significant difference between chronic pancreatitis and PC for frequency of the loss of p16 expression (P < 0.01). Moreover, loss of p16 expression in pancreatic malignancy was significantly associated with histological grade (G1 versus G2 and G3, P < 0.01) but not with sex, age, clinical stage, tumor location, or resectability. The survival period was shorter and metastasis is more likely in those cases that did not show p16 expression than those that did.
使用针对p16蛋白的单克隆抗体（克隆G175 - 405），通过免疫组织化学方法，对石蜡包埋组织中人类原发性胰腺癌（PC）的p16基因产物表达进行了研究，并评估了结果与各种临床病理参数的相关性。6例正常胰腺组织以及20例慢性胰腺炎组织中除1例之外均表达p16蛋白，而8例囊腺瘤中有37.5%（3例）以及62例PC中有41.9%（26例）失去了p16表达。慢性胰腺炎和PC在p16表达缺失频率上存在显著差异（P < 0.01）。此外，胰腺恶性肿瘤中p16表达缺失与组织学分级显著相关（G1与G2和G3相比，P < 0.01），但与性别、年龄、临床分期、肿瘤位置或可切除性无关。与显示p16表达的病例相比，未显示p16表达的病例生存期更短且转移可能性更大。
